文献速递认知障碍与痴呆

基于FDG-PET的机器学习框架支持阿尔茨海默病及相关疾病的神经科决策

An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.
PubMed 文献 · Neurology · 2025-06-27

本研究基于FDG-PET影像开发了名为StateViewer的临床决策支持框架,采用邻居匹配算法检测9种神经退行性表型。在包含3671人的发现队列中,模型灵敏度为0.89±0.03,AUC为0.93±0.02,并在放射科读者研究中显示使用该模型可使正确诊断的 odds 提高3.3±1.1倍。

要点

  • StateViewer框架可检测9种神经退行性表型,灵敏度0.89±0.03,AUC 0.93±0.02。
  • 读者研究中使用该模型辅助诊断,正确诊断 odds 提高3.3±1.1倍。
  • 模型具有高可解释性,有助于解决机器学习工具临床整合的挑战。

核心结论

  • 基于FDG-PET的StateViewer框架分类性能强且可解释性高,能辅助神经科决策。

研究设计与样本

  • 回顾性研究,发现队列来自3项研究及常规临床患者,共3671人,平均年龄68岁,49%报告为女性。
  • 采用嵌套交叉验证评估机器学习性能,并在阿尔茨海默病神经影像学倡议中外部验证。
  • 通过放射科读者研究展示临床整合潜力,聚焦于区分后皮质萎缩与路易体痴呆。

主要发现

  • 模型框架检测9种神经退行性表型的灵敏度为0.89±0.03,AUC为0.93±0.02。
  • 在读者研究中,使用模型的读者正确诊断的 odds 是使用当前标准工作流程读者的3.3±1.1倍。

临床怎么用

  • 该框架可作为临床决策支持系统的基础,辅助神经科医生鉴别神经退行性疾病。
  • 模型的高可解释性有助于其整合到临床工作流程中。

局限性

  • 发现队列较为单一,在某些方面不能代表其他患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Distinguishing neurodegenerative diseases is a challenging task requiring neurologic expertise. Clinical decision support systems (CDSSs) powered by machine learning (ML) and artificial intelligence can assist with complex diagnostic tasks by augmenting user capabilities, but workflow integration poses many challenges. We propose that a modeling framework based on fluorodeoxyglucose PET (FDG-PET) imaging can address these challenges and form the basis of an effective CDSS for neurodegenerative disease. METHODS: This retrospective study focused on FDG-PET images in a discovery cohort drawn from 3 research studies plus routine clinical patients. When selecting research study participants, the inclusion criterion was the availability of an FDG-PET image from within 2.5 years of diagnosis with 1 of 9 specific neurodegenerative syndromes or designation as unimpaired. Participants from disease groups were recruited from the clinical patient population while unimpaired participants came primarily from a population study. The discovery cohort was used to develop a clinical decision support framework we call StateViewer, which applies a neighbor matching algorithm to detect the presence of 9 different neurodegenerative phenotypes. The ML performance of this framework was evaluated in the discovery cohort by nested cross-validation and externally validated in the Alzheimer's Disease Neuroimaging Initiative. Potential for clinical integration was demonstrated in a radiologic reader study focused on differentiating posterior cortical atrophy from Lewy body dementia. RESULTS: The discovery cohort contained 3,671 individuals with a mean age of 68 years and consisted of 49% reported female. Our model framework was able to detect the presence of 9 different neurodegenerative phenotypes with a sensitivity of 0.89 ± 0.03 and an area under the receiver operating characteristic curve of 0.93 ± 0.02. In the radiologic reader study, readers using our model were found to have 3.3 ± 1.1 times greater odds of making a correct diagnosis than readers using a current standard-of-care workflow. DISCUSSION: Our proposed framework provides strong classification performance with high interpretability, and it addresses many of the challenges that face clinical integration of ML-based decision support tools. One limitation of this study is a uniform discovery cohort that is not representative of other patient populations in some regards.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Barnard L, Botha H, Corriveau-Lecavalier N, et al. An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders. Neurology. 2025. PMID: 40577677. doi:10.1212/WNL.0000000000213831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。